Form 4: RA Capital Management Reports Acquisition of Acrivon Therapeutics Stock Options

RA Capital Management and related entities report the acquisition of stock options in Acrivon Therapeutics, Inc. on June 20, 2024.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev M. Shah, filed a Form 4 regarding their beneficial ownership in Acrivon Therapeutics, Inc. (ACRV).
• The report indicates the acquisition of 20,275 stock options with an exercise price of $6.52 on June 20, 2024, expiring on June 19, 2034.
• These options are held by Dr. Derek DiRocco, a Partner of the Adviser, for the benefit of the Fund and the Nexus Fund II, and any proceeds from the exercise of these options will offset advisory fees owed to the Adviser.
• The reporting persons disclaim beneficial ownership of the option and underlying common stock, except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to changes in beneficial ownership. It doesn't convey strong positive or negative sentiment.

Industry Context

This filing reflects standard investment activity by a major investment firm in a publicly traded biopharmaceutical company. It is common for investment firms to hold stock options and other securities in companies they invest in.

Key Dates